EUVIMEDEUVIMED entdecken
Crossref

Cachexia in oncology patients

Beyza Hilal Balcı, Selim Yalçın

Intercontinental Journal of Internal Medicine · 28.02.2026 · 4 (1) · 22-25

DOI: 10.51271/icjim-0070 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Intercontinental Journal of Internal Medicine, online erschienen am 28.02.2026. Verfasst von Beyza Hilal Balcı und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer-related cachexia is a complex metabolic syndrome characterized by involuntary weight loss, systemic inflammation, and a significant disruption of protein-energy homeostasis. It serves as a primary determinant of mortality and negatively impacts the efficacy of oncological treatments such as chemotherapy. The prevalence of cachexia ranges between 40% and 70%, with the highest incidence observed in pancreatic and gastrointestinal cancers. Its pathophysiology is driven by tumor-secreted pro-inflammatory cytokines (e.g., TNF-alfa, IL-1, IL-6), which trigger systemic catabolism, including accelerated proteolysis in skeletal muscles and increased lipolysis in adipose tissue. Furthermore, the syndrome involves the impairment of the central nervous system’s homeostatic control over energy balance, leading to anorexia and high resting energy expenditure. Diagnosis is primarily established through the monitoring of unintentional weight loss and Body Mass Index (BMI), where a weight loss of 5% is identified as a critical threshold for poor prognosis. Effective management requires a multisystemic and multidisciplinary approach. This includes early nutritional interventions (oral, enteral, or parenteral), the use of appetite stimulants (orexigens), and tailored exercise programs to mitigate muscle atrophy. Additionally, comprehensive symptom management—addressing pain, nausea, and psychological distress—is essential for holistic care. As cachexia progresses, it may become resistant to conventional therapies, leading to inevitable decline. Given the increasing global incidence of cancer, there is a critical need for specialized teams and further research to develop effective, targeted treatment strategies for this challenging condition.

Zitieren

APA

Balcı, B. H., & Yalçın, S. (2026). Cachexia in oncology patients. Intercontinental Journal of Internal Medicine, 4(1), 22-25. https://doi.org/10.51271/icjim-0070

Vancouver

Balcı BH, Yalçın S. Cachexia in oncology patients. Intercontinental Journal of Internal Medicine. 2026;4(1):22-25. doi:10.51271/icjim-0070

BibTeX
@article{Balc2026,
  author = {Balcı, Beyza Hilal and Yalçın, Selim},
  title = {Cachexia in oncology patients},
  journal = {Intercontinental Journal of Internal Medicine},
  year = {2026},
  volume = {4},
  number = {1},
  pages = {22--25},
  doi = {10.51271/icjim-0070}
}
Kostenlos starten →